Top Stock Reports for AbbVie, NIKE & BHP
https://www.zacks.com/commentary/2194633/top-stock-reports-for-abbvie-nike-bhp?cid=CS-ZC-FT-research_daily-2194633
Dec 07, 2023 - Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NIKE, Inc. (NKE) and BHP Group Ltd. (BHP).
0
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
https://www.zacks.com/stock/news/2194306/immunogen-imgn-gets-fda-priority-review-for-elahere-sbla?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194306
Dec 06, 2023 - The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
0
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
0